Iranian fund eyes healthcare JVs, investment with a focus on Europe

The move comes amid growing tensions between Iran and the U.S.

The Iranian sovereign fund IFIC says it is looking to invest in healthcare in a bid to help improves the lives of Iranians.

This is according to Vahid Sharif, an investment manager at the 20-year-old, $5 billion fund, who spoke to Reuters at this week’s Global Sovereign Wealth Forum in London, U.K.

While currently injecting cash into nearly two dozen companies, predominately in the financial and heavy industry sectors, Sharif told the newswire that the IFIC “was focusing on opportunities in the healthcare industry, such as pharmaceuticals to tackle cancer and Alzheimer's,” as well as high-tech industries.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

He said that investments could be made by taking minority stakes in companies, or through joint ventures. “We want to transfer knowledge to Iranians,” Sharif said.

In terms of geography, the fund is looking to Europe for now, while also looking at Japan and South Korea.

There was no mention of the U.S., which want to deepen sanctions against the country, with President Donald Trump telling Iran last month that “there’s a new president in town” and that his administration would not “sit by” and allow the country to pursue its military ambitions.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.